Safinamide
- TRADE NAME: Xadago (Newron)
- INDICATIONS: Adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing 'off' episodes
- CLASS: Monoamine oxidase B inhibitor
- HALF-LIFE: 20–26 hours
FDA APPROVAL DATE: 03/21/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Cyclobenzaprine, Dextromethorphan, Dopaminergic antagonists, Imatinib, Irinotecan, Isoniazid, Lapatinib, Linezolid, Meperidine, Methadone, Methylphenidate, Metoclopramide, Mitoxantrone, Other MAO inhibitors, Propoxyphene, Rosuvastatin, Serotonergic drugs, St John's Wort, Sulfasalazine, Sympathomimetics, Topotecan, Tramadol, Tricyclic or tetracyclic antidepressants, Viloxazine
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 10/07/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
